美国高敏肌钙蛋白检测的实施现状与临床影响
该研究分析了2019至2021年美国550家医院251,000例胸痛-MI注册数据,发现高敏肌钙蛋白(hs-cTn)检测使用率从3.3%升至32.6%。hs-cTn使用与NSTE-ACS患者超声心动图使用增加、低危患者有创冠脉造影减少及住院时间轻度缩短相关,但与血运重建或院内死亡无显著关联。
要点
- 美国hs-cTn检测使用率从2019年Q1的3.3%升至2021年Q3的32.6%,但多数医院仍使用低敏感检测。
- hs-cTn使用与NSTE-ACS患者超声心动图增加(82.4% vs 75.0%;aOR 1.43)及低危患者有创造影减少(3.7% vs 4.5%;aOR 0.73)相关。
- hs-cTn使用与住院时间轻度缩短相关(中位47.6 vs 48.0小时;比值0.94),但与血运重建或院内死亡无显著关联。
核心结论
- 美国医院hs-cTn检测实施率在2019至2021年间上升,但多数医院仍使用较低敏感度的检测方法。
- hs-cTn使用与NSTE-ACS患者超声心动图使用增加、低危患者有创冠脉造影减少及住院时间轻度缩短相关,但与血运重建或院内死亡无显著关联。
研究设计与样本
- 研究分析了2019年1月1日至2021年9月30日期间参与国家心血管数据注册胸痛-MI注册的550家医院共251,000例患者。
- 采用广义估计方程模型(logistic或gamma分布)评估hs-cTn使用与院内诊断成像及患者结局的关联。
主要发现
- hs-cTn检测实施率从2019年第一季度的3.3%上升至2021年第三季度的32.6%(P趋势<0.001)。
- hs-cTn使用与NSTE-ACS患者超声心动图使用增加相关(82.4% vs 75.0%;调整OR 1.43;95%CI 1.19-1.73),但在低危胸痛个体中无此关联。
- hs-cTn使用与低危患者有创冠脉造影减少相关(3.7% vs 4.5%;调整OR 0.73;95%CI 0.58-0.92),但在NSTE-ACS患者中无显著差异。
- hs-cTn使用与非侵入性负荷试验或冠状动脉CT血管造影无显著关联。
- 在NSTE-ACS患者中,hs-cTn使用与血运重建或院内死亡无显著关联;hs-cTn使用与住院时间缩短相关(中位47.6小时 vs 48.0小时;比值0.94;95%CI 0.90-0.98)。
临床怎么用
- hs-cTn检测在美国医院逐步推广,临床医生应了解其与超声心动图增加、低危患者有创造影减少及住院时间轻度缩短的关联。
- 对于NSTE-ACS患者,hs-cTn使用未显示与血运重建或院内死亡改善相关,需结合其他临床决策。
- 低危胸痛患者使用hs-cTn可能减少不必要的有创冠脉造影。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few data exist regarding the implementation of high-sensitivity cardiac troponin (hs-cTn) assays in the United States since their approval. OBJECTIVES: This study sought to explore trends in hs-cTn assay implementation over time and assess the association of their use with in-hospital cardiac testing and outcomes. METHODS: The study examined trends in implementation of hs-cTn assays among participating hospitals in the National Cardiovascular Data Registry Chest Pain-MI [Myocardial Infarction] Registry from January 1, 2019 through September 30, 2021. Associations among hs-cTn use, use of in-hospital diagnostic imaging, and patient outcomes were assessed using generalized estimating equation models with logistic or gamma distributions. RESULTS: Among 550 participating hospitals (N = 251,000), implementation of hs-cTn assays increased from 3.3% in the first quarter of 2019 to 32.6% in the third quarter of 2021 (Ptrend < 0.001). Use of hs-cTn was associated with more echocardiography among persons with non-ST-segment elevation acute coronary syndrome (NSTE-ACS; 82.4% vs 75.0%; adjusted odds ratio: 1.43; 95% CI: 1.19-1.73) but not among low-risk chest pain individuals. Use of hs-cTn was associated with less invasive coronary angiography among low-risk patients (3.7% vs 4.5%; adjusted odds ratio: 0.73; 95% CI: 0.58-0.92) but similar use for patients with NSTE-ACS. There was no association between hs-cTn use and noninvasive stress testing or coronary computed tomography angiography testing. Among individuals with NSTE-ACS, hs-cTn use was not associated with revascularization or in-hospital mortality. Use of hs-cTn was associated with a shorter length of stay (median 47.6 hours vs 48.0 hours; ratio: 0.94; 95% CI: 0.90-0.98). CONCLUSIONS: Implementation of hs-cTn among U.S. hospitals is increasing, but most U.S. hospitals continue to use less sensitive assays. The use of hs-cTn was associated with modestly shorter length of stay, greater use of echocardiography for NSTE-ACS, and less use of invasive angiography among low-risk patients.
引用
- McCarthy, Li, Wang, et al. Implementation of High-Sensitivity Cardiac Troponin Assays in the United States. J Am Coll Cardiol. 2022. PMID: 36328155. doi:10.1016/j.jacc.2022.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。